NEW YORK (GenomeWeb) – KineMed and Pronutria Biosciences today announced a collaboration to use KineMed's proteomics platform to evaluate Pronutria's biologics.

Pronutria is developing biologics to restore cellular homeostasis for patients with muscle, neurological, liver, and metabolic disorders and will use the KineMed platform to assess the physiologic effects of its compounds in preclinical and clinical studies.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.